Boehringer Ingelheim plans Phase III AML trial for volasertib
This article was originally published in Scrip
Executive Summary
Boehringer Ingelheim said it expects to begin a Phase III trial of its investigational hematology/oncology compound, volasertib, early next year after reporting positive results from the Phase II part of a Phase I/II trial in acute myeloid leukemia.